{"url":"https://lda.senate.gov/api/v1/filings/80d7135c-e263-4c41-9fde-0e4bbee5c8c0/","filing_uuid":"80d7135c-e263-4c41-9fde-0e4bbee5c8c0","filing_type":"Q3","filing_type_display":"3rd Quarter - Report","filing_year":2017,"filing_period":"third_quarter","filing_period_display":"3rd Quarter (July 1 - Sep 30)","filing_document_url":"https://lda.senate.gov/filings/public/filing/80d7135c-e263-4c41-9fde-0e4bbee5c8c0/print/","filing_document_content_type":"text/html","income":"50000.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"W. Christopher Lamond","dt_posted":"2017-10-19T16:55:44.053000-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"100 M Street, SE","registrant_address_2":"Suite 750","registrant_different_address":false,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20003","registrant":{"id":400534596,"url":"https://lda.senate.gov/api/v1/registrants/400534596/","house_registrant_id":41161,"name":"THORN RUN PARTNERS","description":"Government Affairs Firm","address_1":"100 M Street, SE","address_2":"Suite 750","address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20003","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"W. CHRISTOPHER LAMOND","contact_telephone":"+1 202-688-0225","dt_updated":"2026-07-09T09:06:40.882848-04:00"},"client":{"id":192571,"url":"https://lda.senate.gov/api/v1/clients/192571/","client_id":797,"name":"SUNOVION PHARMACEUTICALS INC.","general_description":"pharmaceutical company","client_government_entity":false,"client_self_select":null,"state":"MA","state_display":"Massachusetts","country":"US","country_display":"United States of America","ppb_state":"MA","ppb_state_display":"Massachusetts","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2015-04-01"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"DEA scheduling of pharmaceuticals","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":55359,"prefix":null,"prefix_display":null,"first_name":"CATHERINE","nickname":null,"middle_name":null,"last_name":"FINLEY","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":57978,"prefix":null,"prefix_display":null,"first_name":"BILLY","nickname":null,"middle_name":null,"last_name":"WYNNE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":52116,"prefix":null,"prefix_display":null,"first_name":"GARY","nickname":null,"middle_name":null,"last_name":"PALMQUIST","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"VET","general_issue_code_display":"Veterans","description":"Funding issues related to the VA Epilepsy Centers for Excellence.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":55359,"prefix":null,"prefix_display":null,"first_name":"CATHERINE","nickname":null,"middle_name":null,"last_name":"FINLEY","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":57978,"prefix":null,"prefix_display":null,"first_name":"BILLY","nickname":null,"middle_name":null,"last_name":"WYNNE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":52116,"prefix":null,"prefix_display":null,"first_name":"GARY","nickname":null,"middle_name":null,"last_name":"PALMQUIST","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"H.R.1628, American Health Care Act of 2017/Better Care Reconciliation Act of 2017.\nMedicare Part D, Medicaid reform, mental and neurological health issues.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":55359,"prefix":null,"prefix_display":null,"first_name":"CATHERINE","nickname":null,"middle_name":null,"last_name":"FINLEY","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":57978,"prefix":null,"prefix_display":null,"first_name":"BILLY","nickname":null,"middle_name":null,"last_name":"WYNNE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":52116,"prefix":null,"prefix_display":null,"first_name":"GARY","nickname":null,"middle_name":null,"last_name":"PALMQUIST","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}